Autores

Houman Armirfarzan, Jessica L. Shanahan, Roman Schuman, Kay B. Leissner

Publicação: Therapeutic Advances in Respiratory Disease 2020, Vol. 14: 1–3
Ano: 30 de agosto de 2020
DOI: https://doi.org/10.1177/1753466620951032

Download

https://journals.sagepub.com/doi/pdf/10.1177/1753466620951032

Abstract:

In late December 2019, clusters of patients with interstitial pneumonia of unknown cause were reported by some local health facilities in Wuhan (China). The Chinese Centre for Disease Control conducted an epidemiologic and etiologic investigation, leading to the identification of a novel coronavirus (SARS-CoV-2).1, 2 On March 11th, the World Health Organization (WHO) declared the novel coronavirus disease (COVID-19) a pandemic. In the area of Wuhan, COVID-19 mainly affected male patients (around 60%), with a median age of about 50 years; 40% of patients developed Acute Respiratory Distress Syndrome (ARDS) 5% requiring intensive care. The mortality rate was around 2%.3, 4 However, Grasselli et al. found that the mortality was 26% in ICU. The death rate was higher among those who were older.